Two-Drug combo aims to outsmart resistant hodgkin lymphoma
NCT ID NCT04788043
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while pembrolizumab helps the immune system attack them. The trial enrolls 8 adults and measures how many achieve a complete response after 4 and 8 months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- magrolimab and pembrolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with Hodgkin lymphoma that has not responded to other therapies.
- What could go wrong
- This is a small, early-phase trial with only 8 participants, so results may not apply broadly. The combination may cause side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Stanford University
Stanford, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Could bone marrow from deceased donors cure blood cancers?
- Could an ALS drug clear the fog of chemo brain?